AIP
CARM

Ameritas Investment Partners’s Carisma Therapeutics CARM Stock Holding History

Ameritas Investment Partners’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,202
Closed -$5K – 3142
2024
Q1 		$5K Hold
2,202
– – ﹤0.01% 2948
2023
Q4 		$6.45K Hold
2,202
– – ﹤0.01% 2933
2023
Q3 		$9.31K Hold
2,202
– – ﹤0.01% 2859
2023
Q2 		$19.3K Buy
+2,202
New +$12K ﹤0.01% 2581
2022
Q2 		– Sell
-670
Closed -$8K – 3087
2022
Q1 		$8K Hold
670
– – ﹤0.01% 2851
2021
Q4 		$11K Hold
670
– – ﹤0.01% 2859
2021
Q3 		$11K Hold
670
– – ﹤0.01% 2904
2021
Q2 		$62K Buy
+670
New +$42.7K ﹤0.01% 2042

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameritas Investment Partners's CARM Position: Q2 2024 in Review

Ameritas Investment Partners sold out of Carisma Therapeutics (CARM) in Q2 2024, closing a stake of 2,202 shares — an estimated $5K sold.

Ameritas Investment Partners first reported a position in CARM in Q2 2021 and held it in 8 quarters. The position peaked at $62K in Q2 2021. 53 funds tracked by Wall St. Rank hold CARM as of Q2 2024.

  • Ameritas Investment Partners reported no remaining Carisma Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Ameritas Investment Partners sold 2,202 Carisma Therapeutics shares in Q2 2024, an estimated $5K.
  • Ameritas Investment Partners first reported a position in Carisma Therapeutics in Q2 2021 and held it in 8 quarters.
  • Ameritas Investment Partners's Carisma Therapeutics position peaked at $62K in Q2 2021.
  • 53 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2024.

Based on Ameritas Investment Partners's 13F filing for Q2 2024, filed 13 Aug 2024.